- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04982744
Registry of Li Fraumeni and Li Fraumeni Like Syndromes (ReLF)
Registry of Li Fraumeni and Li Fraumeni Like Syndromes - Registro Della Sindrome di Li Fraumeni Classica e Li Fraumeni Like
Study Overview
Status
Conditions
Detailed Description
The common way to collect patient information is frequently chaotic and inconvenient (sometimes even unsafe), particularly when dealing with rare diseases. The need to simplify the diagnostic process and to overcome the difficulties of data storage and analysis, suggested in 2020 to implement the Registry of Li Fraumeni and Li Fraumeni Like syndromes (ReLF)
The ReLFrelies on an IT Platform named GeDI (Genotype-phenotype Data Integration platform). This solution, realized by a collaboration among Department of Rare Skeletal Disorders and a local software-house (NSI - Nier IT Solution), is a GDPR-compliant, multi-client, web-accessible system and it has been designed according to current medical informatics standards (Orphacode, ICD-10, Human Genome Variants Society, Findability Accessibility Interoperability Reusability -FAIR- Principles). GeDI is continuously implemented to improve management of persons with Osteogenesis Imperfecta and to help researchers in analysing collected information. ROI is articulated in main sections:
Ø Personal data: it comprises general information, birth details and residence data Ø Patient data: including the patients internal code, the hospital code and other details on patients Ø Diagnosis: the diagnosis, the status (affected, suspect, etc.), age at diagnosis, comorbidities, allergies, etc.
Ø Genogram: a tool to design family transmission of the disease, flanked by info on diseases status of all included relatives.
Ø Clinical events: records several signs and symptoms of Li Fraumeni and Li Fraumeni like syndromes (representing the main disease features) and 12 additional items to describe the disease Ø Genetic Analysis and Alteration: including technique, sample information, duration of analysis, etc. In addition, this section comprises detailed information on detected pathological variants (gene, international reference, DNA change, Protein change, genomic position, etc.).
Ø Visits: it includes the typology of the visit (genetic, orthopaedic, rehabilitation, paediatric, etc.), the date of the visit, treatment, prescription, imaging, etc.
Ø Surgeries: this section contains information on the surgeries type, the age of the patients, the site/localization of the procedures, etc.
Ø Documents: this repository is allowed to store all type of documents (radiological reports, imaging, consents, clinical reports, etc.).
Ø Consents: this section comprises a complete overview of all collected consents, including the date of collection.
Ø Samples: it comprises the type of samples (DNA, tissue, whole peripheral blood, etc.)
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Luca Sangiorgi, MD, PhD
- Phone Number: +39-0516366342
- Email: luca.sangiorgi@ior.it
Study Contact Backup
- Name: Marina Mordenti, PhD
- Phone Number: +39-0516366062
- Email: marina.mordenti@ior.it
Study Locations
-
-
Emilia Romagna
-
Bologna, Emilia Romagna, Italy, 40136
- Recruiting
- IRCCS Istituto Ortopedico Rizzoli
-
Contact:
- Marina Mordenti, PhD
- Phone Number: +39 051 6366062
- Email: marina.mordenti@ior.it
-
Contact:
- Manila Boarini, MSc
- Phone Number: +39 051 6366062
- Email: manila.boarini@ior.it
-
Bologna, Emilia Romagna, Italy, 40136
- Enrolling by invitation
- IRCCS Istituto Ortopedico Rizzoli
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients affected by Li Fraumeni or Li Fraumeni Like syndromes
Exclusion Criteria:
- Any condition unrelated to Li Fraumeni or Li Fraumeni Like syndromes
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Other
Cohorts and Interventions
Group / Cohort |
---|
Patients affected by Li Fraumeni and Li Fraumeni Like syndromes
The group comprises all patients affected by Li Fraumeni and Li Fraumeni Like syndromes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Natural History and Epidemiology
Time Frame: Since the disease is rare, the timeframe is strictly related to patients enrolment and consequently to amount of collected data. Considering the low prevalence of this disease, the time frame is up to 10 years.
|
Assessment of epidemiological information (incidence, prevalence measured as percentages and/or ratios). Anthropometric data: weight in kg, height in cm. In addition, weight and height will be combined to report BMI as kg/m^2 Clinical details of the tumor: site of the lesion, number of recurrence(s), presence/absence of metastasis, size of lesion in cm^3 Additional clinical data: type of surgery, age at surgery in years are updated at each follow up and retrospectively (when possible). Clinical reports, medical charts and imaging are the primary source of data. |
Since the disease is rare, the timeframe is strictly related to patients enrolment and consequently to amount of collected data. Considering the low prevalence of this disease, the time frame is up to 10 years.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Genotype-Phenotype Correlation
Time Frame: The timeframe is strictly related to patients enrolment and consequently to amount of collected data. Considering the low prevalence of this disease, the time frame is up to 10 years.
|
The secondary outcome comprises the correlation between genotype and phenotype. This includes, but is not limited to, clinical features and genetic background. This will be pursued using the information collected during visits and follow-ups and the genetic information resulting from molecular investigations. Collection of genetics background (target gene, type of mutation, clinical significance are reported following HGVS nomenclature) and family history (in terms of inheritance by maternal or paternal line). Anthropometric data (weight in kg, height in cm. In addition, weight and height will be combined to report BMI in kg/m^2), clinical details (site of the lesion, recurrence, metastasis), orthopaedic and functional features are updated at each follow up. |
The timeframe is strictly related to patients enrolment and consequently to amount of collected data. Considering the low prevalence of this disease, the time frame is up to 10 years.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Inter- and intra-familial oncological characterization
Time Frame: The timeframe is strictly related to patients enrolment and consequently to amount of collected data. Considering the low prevalence of this disease, the time frame is up to 10 years.
|
This outcome aims to investigate similarities and difference of tumoral manifestation (site of the tumor, type of tumor, age at onset, grade of leasion) in patients affected by Li Fraumeni or Li Fraumeni Like syndromes within the families and among the families.
|
The timeframe is strictly related to patients enrolment and consequently to amount of collected data. Considering the low prevalence of this disease, the time frame is up to 10 years.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Luca Sangiorgi, MSc, Istituto Ortopedico Rizzoli
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 579/2020/Oss/IOR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Li-Fraumeni Syndrome
-
Gustave Roussy, Cancer Campus, Grand ParisCompleted
-
Abramson Cancer Center of the University of PennsylvaniaChildren's Hospital of PhiladelphiaRecruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingLi-Fraumeni SyndromeUnited States
-
Dana-Farber Cancer InstituteActive, not recruiting
-
The Hospital for Sick ChildrenEnrolling by invitation
-
Institute of Cancer Research, United KingdomCancer Research UK; National Institute for Health Research, United KingdomCompletedLi-Fraumeni SyndromeUnited Kingdom
-
National Cancer Institute (NCI)CompletedLi-Fraumeni SyndromeUnited States
-
National Cancer Institute (NCI)RecruitingNeoplasms | Li-Fraumeni Syndrome | Tp53 MutationsUnited States
-
Yang LiRuijin HospitalRecruitingPediatric Cancer | Li-Fraumeni Syndrome | p53 MutationsChina
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI); Baylor College of Medicine; City of Hope Medical...RecruitingTP53 Gene Mutation | Li-Fraumeni Syndrome | Hereditary Cancer Syndrome | Mosaicism | Clonal HematopoiesisUnited States